



## **NEWS RELEASE**

Ocumetics Achieves Key Milestone: Laboratory Testing Confirms  
Accommodative Power Target was Successfully Achieved in Preparation for First-in-Human Trials

### **For Immediate Release**

**Calgary, Alberta – May 8, 2025** - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce a significant breakthrough in its development of next-generation intraocular lens technology. In recent laboratory testing, the Company successfully demonstrated accommodative power change using 3D-printed moulded lenses under simulated ciliary body compression conditions - marking a pivotal step forward in the pursuit of restoring youthful vision. Accommodative power refers to the eye’s ability to focus between near and far distances following lens replacement surgery.

Dean Burns, CEO of Ocumetics, stated: “These results represent a critical milestone for Ocumetics and for the future of ophthalmology. The data supports our confidence in the platform and strengthens our commitment to delivering a lens that not only corrects vision but restores the natural focusing ability lost with age. Our next steps will continue to focus on preparing for our first-in-human studies, planned for summer 2025.”

The testing was conducted using Ocumetics’ Lens Analyzer (IOLA) bench testing platform. By simulating theoretical ciliary body pressures, researchers were able to evaluate the lens’ quality and ability to respond dynamically - mimicking the natural process of accommodation in the human eye. The results confirm that the moulded lens design delivers the accommodative response necessary to move forward confidently toward human trials.

Dr. Garth Webb, Founder and Chief Scientific Officer of Ocumetics, commented on the breakthrough: “This achievement validates years of innovation and perseverance. Demonstrating measurable accommodative power in a laboratory setting using our moulded lens design confirms the foundational science behind the Ocumetics Lens. We are now closer than ever to redefining how we approach vision restoration.”

The Company continues to move forward with a rigorous R&D roadmap, with ongoing collaboration among leading ophthalmic researchers, engineers, and clinical advisors. The Company expects to provide regular updates to the market as it advances to a first-in-human trial expected to commence this summer. Ocumetics remains committed to pioneering solutions that offer patients a true alternative to conventional vision correction technologies.

## About Ocumetics

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry. Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses. It is designed to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.

### **FOR FURTHER INFORMATION, PLEASE CONTACT:**

Dean Burns  
President and CEO  
(817) 874-7564

Roger Jewett  
Chief Financial Officer  
roger.jewett@ocumetics.com

***Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.***

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the research and development to be conducted by the Corporation mentioned above. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.